Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Haixi Pharmaceuticals CoHKSE:02637 +3.28%23 Interest Coverage is 34.42 as of Dec. 2025, which is 92% above its 10-year median of 17.89. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 682 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks better than 65.98% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Fujian Haixi Pharmaceuticals Co's
Operating Income
for the
six
months ended in Dec. 2025 was HK$218.1 Mil. Fujian Haixi Pharmaceuticals Co's Interest Expense for the
six
months ended in Dec. 2025 was HK$-6.3 Mil.
Fujian Haixi Pharmaceuticals Co's interest coverage for the quarter that ended in Dec. 2025 was 34.42.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Fujian Haixi Pharmaceuticals Co's Interest Coverage or its related term are showing as below:
HKSE:02637'
s Interest Coverage Range Over the Past 10 Years
Min: 3.28 Med: 17.89 Max: 34.42
Current: 34.42
HKSE:02637's Interest Coverage is ranked better than 65.98% of 682
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs HKSE:02637: 34.42
Fujian Haixi Pharmaceuticals Co (HKSE:02637) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Fujian Haixi Pharmaceuticals Co Interest Coverage Related Terms
Fujian Haixi Pharmaceuticals Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Fujian Haixi Pharmaceuticals Co Interest Coverage Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Interest Coverage
3.28
16.30
19.47
34.42
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Interest Coverage
3.28
16.30
19.47
34.42
HKSE:02637 vs ZTS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's Interest Coverage falls into.
Fujian Haixi Pharmaceuticals Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a Interest Coverage of 34.42 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is 92% above median its historical median of 17.89. Over the past decade, Fujian Haixi Pharmaceuticals Co's Interest Coverage has ranged from 3.28 to 34.42. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #232 out of 682 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Fujian Haixi Pharmaceuticals Co's Interest Coverage too high?
Fujian Haixi Pharmaceuticals Co's current Interest Coverage of 34.42 is 92% above median its 10-year median of 17.89. Over the past 10 years, this metric has ranged from a low of 3.28 to a high of 34.42. The Drug Manufacturers industry median Interest Coverage is 12.77. Fujian Haixi Pharmaceuticals Co's value of 34.42 is 169.6% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #232 out of 682 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #232 out of 682 companies for Interest Coverage. This puts Fujian Haixi Pharmaceuticals Co in the upper half of its industry. The industry median Interest Coverage is 12.77. Fujian Haixi Pharmaceuticals Co's value of 34.42 is 169.6% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own Interest Coverage has ranged from 3.28 to 34.42 over the past decade. While the company's 10-year median is 17.89 vs. the industry median of 12.77, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current Interest Coverage of 34.42 is 169.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current Interest Coverage is 34.42, which is 92% above median its own 10-year median of 17.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current Interest Coverage of 34.42. The current Interest Coverage is 34.42, which is 92% above median its 10-year median of 17.89 and 169.6% above the Drug Manufacturers industry median of 12.77. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current Interest Coverage is 34.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
